We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    bezafibrate and obeticholic acid
Previous Study | Return to List | Next Study

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05239468
Recruitment Status : Recruiting
First Posted : February 15, 2022
Last Update Posted : April 25, 2023
Sponsor:
Information provided by (Responsible Party):
Intercept Pharmaceuticals

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).

Condition or disease Intervention/treatment Phase
Primary Biliary Cholangitis Drug: Bezafibrate 100 mg Drug: Bezafibrate 200 mg Drug: Obeticholic Acid 5 mg Drug: Obeticholic Acid placebo Drug: Bezafibrate Placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis
Actual Study Start Date : March 21, 2022
Estimated Primary Completion Date : August 2024
Estimated Study Completion Date : August 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Double Blind (DB) Phase Treatment A: BZF 100 milligrams (mg) Immediate Release (IR) tablet
Each Participant will take one OCA placebo tablet, one BZF 100 mg IR tablet and one BZF placebo tablet daily.
 Drug: Bezafibrate 100 mg
One tablet of bezafibrate 100 mg IR once daily

Drug: Obeticholic Acid placebo
One tablet of obeticholic acid placebo tablet once daily

Drug: Bezafibrate Placebo
One tablet of bezafibrate placebo tablet once daily
Active Comparator: Double Blind (DB) Phase Treatment B: BZF 400 mg IR tablet
Each Participant will take one OCA placebo tablet and two BZF 200 mg IR tablets (to achieve 400 mg dose) daily.
 Drug: Bezafibrate 200 mg
Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR

Drug: Obeticholic Acid placebo
One tablet of obeticholic acid placebo tablet once daily
Experimental: Double Blind (DB) Phase Treatment C: OCA 5 mg + BZF 100 mg IR
Each participant will take one OCA 5 mg tablet, one BZF 100 mg IR tablet and one BZF placebo tablet, daily.
 Drug: Bezafibrate 100 mg
One tablet of bezafibrate 100 mg IR once daily

Drug: Obeticholic Acid 5 mg
One tablet of obeticholic acid 5 mg tablet once daily.

Drug: Bezafibrate Placebo
One tablet of bezafibrate placebo tablet once daily
Experimental: Double Blind (DB) Phase Treatment D: OCA 5 mg + BZF 400 mg IR
Each participant will take one OCA 5 mg tablet and two BZF 200 mg IR tablets (to achieve 400 mg dose) daily.
 Drug: Bezafibrate 200 mg
Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR

Drug: Obeticholic Acid 5 mg
One tablet of obeticholic acid 5 mg tablet once daily.
Experimental: Long Term Safety Extension (LTSE) Phase Treatment D of the DB phase: OCA 5 mg + BZF 400 mg IR
Each participant will take one OCA 5 mg tablet and two BZF 200 mg IR tablets (to achieve 400 mg dose) daily.
 Drug: Bezafibrate 200 mg
Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR

Drug: Obeticholic Acid 5 mg
One tablet of obeticholic acid 5 mg tablet once daily.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in Alkaline Phosphatase (ALP) from Baseline to Week 12 [ Time Frame: Baseline, and at Weeks 2, 4, 6, 8, 10 and 12 ]

Secondary Outcome Measures :
  1. Change from Baseline in response rates of ≥10 percent, ≥20 percent, ≥30 percent and ≥40 percent reduction and normalization rates of biochemical disease marker ALP [ Time Frame: Baseline and at Weeks 2, 4, 6, 8, 10 and 12 ]
  2. Number of participants with normalization rates of alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), alanine aminotransferase (AST), total and conjugated bilirubin and lipid panel [ Time Frame: Baseline and at Weeks 2, 4, 6, 8, 10 and 12 ]
  3. Change from Baseline in biochemical disease marker GGT [ Time Frame: Baseline and at Weeks 2, 4, 6, 8, 10 and 12 ]
  4. Change from Baseline in biochemical disease marker ALT [ Time Frame: Baseline and at Weeks 2, 4, 6, 8, 10 and 12 ]
  5. Change from Baseline in biochemical disease marker AST [ Time Frame: Baseline and at Weeks 2, 4, 6, 8, 10 and 12 ]
  6. Change from Baseline in biochemical disease markers, total & conjugated bilirubin [ Time Frame: Baseline and at Weeks 2, 4, 6, 8, 10 and 12 ]
  7. Change from Baseline in lipid panel [ Time Frame: Baseline and at Weeks 2, 4, 6, 8, 10 and 12 ]
  8. Change from Baseline of the plasma value of 7 alpha (α) hydroxy 4 cholesten-3 one (C4) [ Time Frame: Baseline and at Weeks 2, 4, 6, 8, 10, and 12 ]
  9. Change from Baseline of the plasma value of bile acids, in unit of nanograms per milliliter (ng/ml) [ Time Frame: Baseline and at Weeks 2, 4, 6, 8, 10, and 12 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A definite or probable diagnosis of PBC
  • Qualifying ALP and/or bilirubin liver biochemistry values
  • Taking ursodeoxycholic acid (UDCA) for at least 12 months or no UDCA for 3 months before Day 1

Exclusion Criteria:

  • History or presence of other concomitant liver diseases
  • Presence of clinical complications of PBC
  • History or presence of decompensating events
  • Current or history of gallbladder disease
  • If female, known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating
  • Treatment with commercially available OCA or participation in a previous study involving OCA, or other farnesoid X receptor (FXR) agonists, or peroxisome proliferator activated receptor (PPAR)-agonists within 3 months before Screening
  • Unable to tolerate BZF or other fibrates, treatment with commercially available fibrates, or participation in a previous study involving fibrate within 3 months before Screening.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05239468


Contacts
Layout table for location contacts
Contact: Erminia Cafasso 1-973-945-9359 erminia.cafasso@interceptpharma.com

Locations
Show Show 32 study locations
Sponsors and Collaborators
Intercept Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Lynda Szczech, M.D. Intercept Pharmaceuticals, Inc
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Intercept Pharmaceuticals
ClinicalTrials.gov Identifier: NCT05239468    
Other Study ID Numbers: 747-214
First Posted: February 15, 2022    Key Record Dates
Last Update Posted: April 25, 2023
Last Verified: April 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Intercept Pharmaceuticals:
Primary Biliary Cholangitis
Primary Biliary Cirrhosis
Hepatic Impairment
Cirrhosis
Liver
Additional relevant MeSH terms:
Layout table for MeSH terms
Chenodeoxycholic Acid
Bezafibrate
Cholangitis
Liver Cirrhosis, Biliary
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases
Cholestasis, Intrahepatic
Cholestasis
Liver Diseases
 Liver Cirrhosis
Fibrosis
Pathologic Processes
Cathartics
Gastrointestinal Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents